CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Contract with Customer, Asset, Reclassified to Receivable
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Contract with Customer, Asset, Reclassified to Receivable of $204.00 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes
us-gaap:ContractWithCustomerAssetReclassifiedToReceivable · last filed 2023-11-08
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2023-09-30 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2023-07-01 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2023-04-01 was $204.00M, a 26.71% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2022-09-24 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for fiscal 2021 was $135.00M, a 10.66% increase from fiscal 2020.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for fiscal 2020 was $122.00M, a 16.19% increase from fiscal 2019.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for fiscal 2019 was $105.00M, a 14.13% increase from fiscal 2018.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. contract with customer, asset, reclassified to receivable for fiscal 2018 was $92.00M.
| Period end | Contract with Customer, Asset, Reclassified to Receivable 3 month | Contract with Customer, Asset, Reclassified to Receivable 6 month | Contract with Customer, Asset, Reclassified to Receivable 9 month | Contract with Customer, Asset, Reclassified to Receivable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $204.00M 10-Q · filed 2023-11-08 | |
| 2023-07-01 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $204.00M 10-Q · filed 2023-08-09 | ||
| 2023-04-01 | $204.00M 10-Q · filed 2023-05-11 | |||
| 2022-09-24 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $161.00M 10-Q · filed 2023-11-08 | $161.00M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-25 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $161.00M 10-Q · filed 2023-08-09 | $161.00M derived: sum of 3 quarters · filed 2023-08-09 | $161.00M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-26 | $161.00M 10-Q · filed 2023-05-11 | $161.00M derived: sum of 2 quarters · filed 2023-05-11 | $161.00M derived: sum of 3 quarters · filed 2023-05-11 | $161.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-25 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 derived: sum of 3 quarters · filed 2022-11-02 | $135.00M 10-K · filed 2022-02-16 |
| 2021-09-25 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $135.00M 10-Q · filed 2022-11-02 | $135.00M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-26 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $135.00M 10-Q · filed 2022-08-03 | $135.00M derived: sum of 3 quarters · filed 2022-08-03 | $135.00M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-27 | $135.00M 10-Q · filed 2022-05-04 | $135.00M derived: sum of 2 quarters · filed 2022-05-04 | $135.00M derived: sum of 3 quarters · filed 2022-05-04 | $135.00M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-26 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $0.00 derived: sum of 2 quarters · filed 2022-02-16 | $0.00 derived: sum of 3 quarters · filed 2022-02-16 | $122.00M 10-K · filed 2022-02-16 |
| 2020-09-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $122.00M 10-Q · filed 2021-11-03 | |
| 2020-06-27 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $122.00M 10-Q · filed 2021-08-04 | ||
| 2020-03-28 | $122.00M 10-Q · filed 2021-05-04 | |||
| 2019-12-28 | $105.00M 10-K · filed 2021-02-17 | |||
| 2018-12-29 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $13.00M derived: sum of 2 quarters · filed 2019-02-13 | $29.00M derived: sum of 3 quarters · filed 2019-02-13 | $92.00M 10-K · filed 2019-02-13 |
| 2018-09-29 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $25.00M derived: sum of 2 quarters · filed 2018-11-07 | $88.00M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $79.00M 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | $63.00M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |